Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 1
2009 1
2011 1
2012 3
2014 1
2015 6
2016 9
2017 5
2018 11
2019 15
2020 6
2021 11
2022 13
2023 8
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

87 results

Results by year

Filters applied: . Clear all
Page 1
Identification of DAGLA as an autoantibody target in cerebellar ataxia.
Miske R, Scharf M, Borowski K, Specht I, Corty M, Loritz MJ, Rombach F, Laureys G, Rochow N, Radzimski C, Schnitter L, Ratuszny D, Skripuletz T, Wattjes MP, Hahn S, Denno Y, Guerti K, Oyaert M, Benkhadra F, Bien CI, Nitsch S, Wandinger KP, van Pesch V, Probst C, Teegen B, Komorowski L, Sühs KW. Miske R, et al. Among authors: suhs kw. J Neurol Neurosurg Psychiatry. 2024 Apr 25:jnnp-2024-333458. doi: 10.1136/jnnp-2024-333458. Online ahead of print. J Neurol Neurosurg Psychiatry. 2024. PMID: 38663995
Ravulizumab in myasthenic crisis: the first case report.
Konen FF, Jendretzky KF, Ratuszny D, Schuppner R, Sühs KW, Pawlitzki M, Ruck T, Meuth SG, Skripuletz T. Konen FF, et al. Among authors: suhs kw. J Neurol. 2024 May;271(5):2898-2901. doi: 10.1007/s00415-024-12234-2. Epub 2024 Feb 23. J Neurol. 2024. PMID: 38388927 No abstract available.
Different pain phenotypes are associated with anti-Caspr2 autoantibodies.
Greguletz P, Plötz M, Baade-Büttner C, Bien CG, Eisenhut K, Geis C, Handreka R, Klausewitz J, Körtvelyessy P, Kovac S, Kraft A, Lewerenz J, Malter M, Nagel M, von Podewils F, Prüß H, Rada A, Rau J, Rauer S, Rößling R, Seifert-Held T, Siebenbrodt K, Sühs KW, Tauber SC, Thaler F, Wagner J, Wickel J, Leypoldt F, Rittner HL, Sommer C, Villmann C, Doppler K; GENERATE study group. Greguletz P, et al. Among authors: suhs kw. J Neurol. 2024 May;271(5):2736-2744. doi: 10.1007/s00415-024-12224-4. Epub 2024 Feb 22. J Neurol. 2024. PMID: 38386048
Anti-GABA-A Receptor Antibody-Mediated Epilepsia Partialis Continua After Treatment With Alemtuzumab: A Case Report.
Ratuszny D, Skripuletz T, Stüber T, Valizada E, Gehring K, Ertl P, Müller JA, Wattjes MP, Feuerhake F, Sühs KW. Ratuszny D, et al. Among authors: suhs kw. Neurol Neuroimmunol Neuroinflamm. 2023 May 18;10(4):e200123. doi: 10.1212/NXI.0000000000200123. Print 2023 Jul. Neurol Neuroimmunol Neuroinflamm. 2023. PMID: 37202183 Free PMC article.
Treatment of autoimmunity: The impact of disease-modifying therapies in multiple sclerosis and comorbid autoimmune disorders.
Konen FF, Möhn N, Witte T, Schefzyk M, Wiestler M, Lovric S, Hufendiek K, Schwenkenbecher P, Sühs KW, Friese MA, Klotz L, Pul R, Pawlitzki M, Hagin D, Kleinschnitz C, Meuth SG, Skripuletz T. Konen FF, et al. Among authors: suhs kw. Autoimmun Rev. 2023 May;22(5):103312. doi: 10.1016/j.autrev.2023.103312. Epub 2023 Mar 15. Autoimmun Rev. 2023. PMID: 36924922 Free article. Review.
Saliva Free Light Chains in Patients with Neuro-Sjögren.
Konen FF, Seeliger T, Schwenkenbecher P, Gingele S, Jendretzky KF, Sühs KW, Ernst D, Witte T, Skripuletz T. Konen FF, et al. Among authors: suhs kw. Biomedicines. 2022 Oct 3;10(10):2470. doi: 10.3390/biomedicines10102470. Biomedicines. 2022. PMID: 36289732 Free PMC article.
87 results